Regulus Rises On HCV Data, But Will Injection Find A Market?

Regulus Therapeutics Inc. reported positive interim Phase II results for its microRNA-targeting injection RG-101 in a hepatitis C virus (HCV) market that's dominated by highly effective oral drugs, but the company may be able to reach a goal that's been illusive for Gilead Sciences Inc. and its competitors – curing HCV patients with a four-week regimen.

Regulus Therapeutics Inc. reported positive interim Phase II results for its microRNA-targeting injection RG-101 in a hepatitis C virus (HCV) market that's dominated by highly effective oral drugs, but the company may be able to reach a goal that's been illusive for Gilead Sciences Inc. and its competitors – curing HCV patients with a four-week regimen.

San Diego-based Regulus gained 18.5% to close at $7.44 per share after the company said hepatitis C was undetectable in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By 

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

More from Therapy Areas

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.